April 2025

Medical-on-the-Go is happy to share highlights from the recently concluded ATTD Congress 2025 Last March 19-22, 2025 in Amsterdam & online.

September 2024

We would like to update you on a recently published randomized, head-to-head, open label phase 3 trial in Chinese people with Type 2 Diabetes Mellitus suboptimally controlled on OADs entitled the Soli-D study.

June 2024

This real-world observational study by Malik et al. shows that initiation of iGlarLixi in people with T2D suboptimally controlled on OADs ± BI or GLP-1 RAs improves glycemic control with a low incidence of hypoglycaemia.

May 2025

Our global expert highlights that individuals living with Type 2 diabetes (T2D) and renal impairment are a key high-risk population and additional considerations need to be made in the management of diabetes.

In this episode, we delve into the Efficacy and safety of iGlarLixi versus IDegAsp in Chinese adults with type 2 diabetes, based on the findings from the Soli-D randomized controlled trial.

In this episode, Dr Jeremy Pettus and Dr Steve Edelman discuss the increasing role of continuous glucose monitoring (CGM) and time-in-range (TIR) in diabetes management.